Literature DB >> 22963202

Presentation of two patients with malignant granulosa cell tumors, with a review of the literature.

Ryousuke Tamura1, Yoshihito Yokoyama, Takeshi Yanagita, Yukiko Matsumura, Kazuhiro Abe, Ryousuke Taniguchi, Hideki Mizunuma.   

Abstract

Granulosa cell tumors (GCTs) of the ovary account for 2 to 5 of ovarian malignancies. We present two patients with malignant ovarian adult GCT. In one patient, a combination of bleomycin, etoposide, and cisplatin was effective after initial surgery for malignant GCT. In the other, an aromatase inhibitor was effective for recurrent malignant GCT. We also review the literature for further management of this tumor. Because GCT of the ovary is rare, it will be necessary to elucidate the clinical phenotype and establish treatment protocols by accumulating and analyzing more patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22963202      PMCID: PMC3490972          DOI: 10.1186/1477-7819-10-185

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   2.754


  17 in total

1.  Cisplatin (P), vinblastine (V) and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa(-theca) cell tumours of the ovary. An EORTC Gynaecological Cancer Cooperative Group study.

Authors:  S Pecorelli; H C Wagenaar; I B Vergote; D Curran; L V Beex; E Wiltshaw; J B Vermorken
Journal:  Eur J Cancer       Date:  1999-09       Impact factor: 9.162

2.  The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.

Authors:  Jubilee Brown; Hyun S Shvartsman; Michael T Deavers; Lois M Ramondetta; Thomas W Burke; Mark F Munsell; David M Gershenson
Journal:  Gynecol Oncol       Date:  2005-05       Impact factor: 5.482

Review 3.  Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature.

Authors:  Mariam M Alhilli; Harry J Long; Karl C Podratz; Jamie N Bakkum-Gamez
Journal:  J Obstet Gynaecol Res       Date:  2011-12-05       Impact factor: 1.730

4.  Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women.

Authors:  Mallory Zhang; Michael K Cheung; Jacob Y Shin; Daniel S Kapp; Amreen Husain; Nelson N Teng; Jonathan S Berek; Kathryn Osann; John K Chan
Journal:  Gynecol Oncol       Date:  2006-10-09       Impact factor: 5.482

5.  Promising effect of aromatase inhibitors on recurrent granulosa cell tumors.

Authors:  Jacob Korach; Tamar Perri; Mario Beiner; Tima Davidzon; Eddie Fridman; Gilad Ben-Baruch
Journal:  Int J Gynecol Cancer       Date:  2009-07       Impact factor: 3.437

6.  Inhibin alpha and beta expression in ovarian stromal tumors and their histological equivalences.

Authors:  Metin Ciriş; Yildiz Erhan; Osman Zekioglu; Hatice Bayramoglu
Journal:  Acta Obstet Gynecol Scand       Date:  2004-05       Impact factor: 3.636

7.  Characteristics of recurrence in adult-type granulosa cell tumor.

Authors:  Y-K Lee; N-H Park; J W Kim; Y-S Song; S-B Kang; H-P Lee
Journal:  Int J Gynecol Cancer       Date:  2007-09-14       Impact factor: 3.437

8.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

Authors:  John F Forbes; Jack Cuzick; Aman Buzdar; Anthony Howell; Jeffrey S Tobias; Michael Baum
Journal:  Lancet Oncol       Date:  2008-01       Impact factor: 41.316

9.  A late recurring and easily forgotten tumor: ovarian granulosa cell tumor.

Authors:  Yi-Chan Chen; Liang-Che Chang; Ruey-Shyang Soong
Journal:  World J Surg Oncol       Date:  2012-05-16       Impact factor: 2.754

10.  Bilateral aggressive malignant granulosa cell tumour with essentially different immunophenotypes in primary and metastatic lesions comprising predominantly sarcomatoid and fibrothecomatous patterns - looking for prognostic markers: a case report.

Authors:  Wojciech Jozwicki; Anna Aneta Brożyna; Małgorzata Walentowicz; Marek Grabiec
Journal:  Arch Med Sci       Date:  2011-11-08       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.